Bicycle Therapeutics (BCYC) Return on Capital Employed (2019 - 2026)
Bicycle Therapeutics posted quarterly Return on Capital Employed of 38.1% for Q1 2026, down 931.0% year-on-year from 4.58% in Q1 2025, and down 5.44% on a QoQ basis from 36.13% in Q4 2025.
Bicycle Therapeutics (BCYC) has 8 years of Return on Capital Employed data on file, last reported at 38.1% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 931.0% year-over-year to 38.1%; the trailing twelve-month figure through Mar 2026 stood at 38.1% (down 931.0% YoY), and the FY2025 full-year result was 31.66%, down 206.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 38.1%, down from 36.13% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 17.73% in Q1 2022 and bottomed at 39.79% in Q3 2025.
- The 5-year median for Return on Capital Employed is 34.47% (2024), against an average of 30.91%.
- The widest annual swing landed in 2022, when Return on Capital Employed surged 1509 bps; it then plunged 1956 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 32.36% in 2022, then retreated by 7 bps to 34.69% in 2023, then soared by 33 bps to 23.07% in 2024, then sank by 57 bps to 36.13% in 2025, then slipped by 5 bps to 38.1% in 2026.
- The last three Return on Capital Employed figures came in at 38.1% (Q1 2026), 36.13% (Q4 2025), and 39.79% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | -38.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.10% |
| Dec 31, 2025 | -36.13% |
| Sep 30, 2025 | -39.79% |
| Jun 30, 2025 | -36.93% |
| Mar 31, 2025 | -28.79% |
| Dec 31, 2024 | -23.07% |
| Sep 30, 2024 | -20.24% |
| Jun 30, 2024 | -25.03% |
| Mar 31, 2024 | -34.47% |
| Dec 31, 2023 | -34.69% |
| Sep 30, 2023 | -35.23% |
| Jun 30, 2023 | -39.78% |
| Mar 31, 2023 | -35.74% |
| Dec 31, 2022 | -32.36% |
| Sep 30, 2022 | -26.29% |
| Jun 30, 2022 | -21.16% |
| Mar 31, 2022 | -17.73% |
| Dec 31, 2021 | -19.06% |
| Sep 30, 2021 | -28.93% |
| Jun 30, 2021 | -30.26% |
| Mar 31, 2021 | -32.82% |
| Dec 31, 2020 | -36.47% |
| Sep 30, 2020 | -31.16% |
| Jun 30, 2020 | -36.69% |
| Mar 31, 2020 | -33.46% |
| Dec 31, 2019 | -25.21% |
| Sep 30, 2019 | -25.89% |